Kenneth Offit | |
---|---|
![]() | |
Born | Kenneth Offit February 19, 1955 |
Alma mater | Princeton University Harvard Medical School Harvard School of Public Health |
Known for | BRCA2 Research |
Spouse | Emily Sonnenblick (m. 1984) |
Awards | American Society of Clinical Oncology-American Cancer Society Award (2013) |
Scientific career | |
Fields | Cancer Genetics, Oncology, Medical Research |
Institutions | Memorial Sloan Kettering Cancer Center |
Kenneth Offit (born February 19, 1955) is an American cancer geneticist and oncologist known for his discoveries with respect to the genetic bases of breast, colorectal, and lymphoid cancers. [1] He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. [2] Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute and Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College. [3] He was previously a member of both the Board of Scientific Counselors of the National Cancer Institute [4] and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control. [5]
Offit has garnered numerous honors for his contributions to the prevention and management of cancer. In 2013, he was selected for the American Society of Clinical Oncology-American Cancer Society Award and Lecture. [6] [7] In 2016, he was elected as a Member of the National Academy of Medicine [1] and appointed to the Roundtable on Genomics and Precision Health. [8] In 2018, he was named a Fellow of the American Society of Clinical Oncology. [9] In 2021, he was elected a Fellow of the American Association for the Advancement of Science. [10] In 2023, he was awarded University of Pennsylvania's Basser Global Prize for BRCA1 and BRCA2-related research [11] and an Ellis Island Medal of Honor for his national professional and civic contributions. [12]
Offit was born in New York City on February 19, 1955, to Dr. Avodah K. Offit (née Komito), a psychiatrist, and Sidney Offit, an author. [13] Offit attended the Browning School and then Princeton University, where he was chairman of the campus humor magazine, Tiger Magazine. [14] He graduating magna cum laude in 1977 and joined the University Board of Trustees as a young alumni trustee. [13] In this capacity, he worked closely with President William G. Bowen on issues pertaining to Princeton's residential system. [15] In 1979, Offit voted to endorse the proposals of the Committee on Undergraduate Residential Life (CURL) that would become the basis for Princeton's current residential college system. [16] Offit and other trustees would further propose that residential colleges be expanded to include upperclassmen who had not joined a selective eating club—a reform that, with some modification, would be adopted decades later. [15]
After finishing his undergraduate degree, Offit completed an M.D. at Harvard Medical School and an M.P.H. at the Harvard School of Public Health. [13] He then returned to New York for a residency in internal medicine at the Lenox Hill Hospital. Upon finishing the residency in 1985, he moved to Memorial Sloan Kettering Cancer Center for a three-year fellowship in hematology and oncology. [13] [17]
Offit joined the faculty at Memorial Sloan Kettering Cancer Center upon the completion of his fellowship in 1988. [18] His early work involved molecular cytogenetic studies of non-Hodgkin's lymphoma. [18]
In 1992, Offit founded one of the world's first clinical cancer genetics services. [11] In 1996, after the discovery of the BRCA2 gene, he and his research group successfully identified the most common mutation on the gene associated with breast and ovarian cancer among individuals of Ashkenazi Jewish ancestry. [4] [19] [20] [21] [22] Offit would also lead the first American Society of Clinical Oncology policy statement following the identification of BRCA1 and BRCA2. [11] In 1997, he wrote Clinical Cancer Genetics: Risk Counseling and Management, which received an award in Medical Sciences from the Association of American Publishers. [23]
In 2002, Offit and his clinical team published the first prospective study establishing the role of risk-reducing ovarian surgery in women carrying BRCA1 and BRCA2 mutations. [24] [25] They would go on to discover or describe recurrent mutations causing increased risk for colon and prostate cancer, and, in 2013 and 2015, they described two genetic syndromes of inherited childhood lymphoblastic leukemia. [26]
In 2018, Offit joined Beth Karlan, Judy Garber, Susan Domchek, and other physicians to launch the BRCA Founder Outreach Study (BFOR). BFOR provided free testing for three mutations for all insured people over the age of 25 with at least one grandparent of Ashkenazi heritage. [27] Offit called BFOR "a model for the future of genetic testing in health care"—one that would, in contrast to direct-to-consumer genetics testing, allow participants to receive results from their primary care provider. [28]
In 1984, Offit married Emily Sonnenblick. Sonnenblick is a radiologist at Mount Sinai Hospital and the daughter of cardiologist Edmund Sonnenblick. [13] One of their daughters, Anna Offit, is an assistant professor of law at Southern Methodist University. [29]
Breast cancer type 1 susceptibility protein is a protein that in humans is encoded by the BRCA1 gene. Orthologs are common in other vertebrate species, whereas invertebrate genomes may encode a more distantly related gene. BRCA1 is a human tumor suppressor gene and is responsible for repairing DNA.
BRCA2 and BRCA2 are human genes and their protein products, respectively. The official symbol and the official name are maintained by the HUGO Gene Nomenclature Committee. One alternative symbol, FANCD1, recognizes its association with the FANC protein complex. Orthologs, styled Brca2 and Brca2, are common in other vertebrate species. BRCA2 is a human tumor suppressor gene, found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. MSKCC is one of 72 National Cancer Institute-designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.
Mary-Claire King is an American geneticist. She was the first to show that breast cancer can be inherited due to mutations in the gene she called BRCA1. She studies human genetics and is particularly interested in genetic heterogeneity and complex traits. She studies the interaction of genetics and environmental influences and their effects on human conditions such as breast and ovarian cancer, inherited deafness, schizophrenia, HIV, systemic lupus erythematosus and rheumatoid arthritis. She has been the American Cancer Society Professor of the Department of Genome Sciences and of Medical Genetics in the Department of Medicine at the University of Washington since 1995.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
Hereditary breast–ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal levels of breast cancer, ovarian cancer and additional cancers in genetically related families. It accounts for 90% of the hereditary cancers. The hereditary factors may be proven or suspected to cause the pattern of breast and ovarian cancer occurrences in the family. The name HBOC may be misleading because it implies that this genetic susceptibility to cancer is mainly in women. In reality, both sexes have the same rates of gene mutations and HBOC can predispose to other cancers including prostate cancer and pancreatic cancer. For this reason, the term "King syndrome" has recently come into use. The new name references Mary-Claire King who identified the genes BRCA1 and BRCA2.
TOX high mobility group box family member 3, also known as TOX3, is a human gene.
A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome in affected persons. Only 5–10% of breast cancer cases in women are attributed to BRCA1 and BRCA2 mutations, but the impact on women with the gene mutation is more profound. Women with harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal. The risk of breast and ovarian cancer is higher for women with a high-risk BRCA1 mutation than with a BRCA2 mutation. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
A hereditary cancer syndrome is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancer and may also cause early onset of these cancers. Hereditary cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors.
Henry Thompson Lynch was an American physician noted for his discovery of familial susceptibility to certain kinds of cancer and his research into genetic links to cancer.
A variant of uncertainsignificance (VUS) is a genetic variant that has been identified through genetic testing but whose significance to the function or health of an organism is not known. Two related terms are "gene of uncertain significance" (GUS), which refers to a gene that has been identified through genome sequencing but whose connection to a human disease has not been established, and "insignificant mutation", referring to a gene variant that has no impact on the health or function of an organism. The term "variant' is favored in clinical practice over "mutation" because it can be used to describe an allele more precisely. When the variant has no impact on health, it is called a "benign variant". When it is associated with a disease, it is called a "pathogenic variant". A "pharmacogenomic variant" has an effect only when an individual takes a particular drug and therefore is neither benign nor pathogenic.
Nikola Panayot Pavletich is the former chair of structural biology at Memorial Sloan Kettering Cancer Center.
Maria Jasin is a developmental biologist at the Memorial Sloan Kettering Cancer Center. She is known for studying homologous recombination, a method in which double-strand breaks in DNA strands are repaired, and for discovering the role of BRCA1 and BRCA2 in cancers.
Jórunn Erla Eyfjörð is an Icelandic molecular biologist and professor emerita at the Faculty of Medicine of the University of Iceland. She is known for her research on breast cancer genetics.
Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.
Deborah Schrag is the George H. Bosl Chair at Memorial Sloan Kettering Cancer Center. She is a medical oncologist known for her work in patient care and examination of patient outcomes.
Breast and ovarian cancer does not necessarily imply that both cancers occur at the same time, but rather that getting one cancer would lead to the development of the other within a few years. Women with a history of breast cancer have a higher chance of developing ovarian cancer, vice versa.
{{cite web}}
: Missing or empty |title=
(help){{cite web}}
: CS1 maint: bot: original URL status unknown (link){{cite news}}
: CS1 maint: url-status (link)